Article
Dr Robert Gabbay Talks About Adding Finenerone as a Recommended Drug in New ADA Guidelines
Author(s):
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), breaks down the reasoning behind the organization's decision to add Bayer's Kerendia (finerenon) as a recommended drug for kidney disease prevention.
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), breaks down the reasoning behind the organization's decision to add Bayer's Kerendia (finerenone) as a recommended drug for kidney disease prevention.
Transcript
What went into the ADA’s decision to add a recommendation for the use of Bayer’s Kerendia (finerenone) for preventing CKD progression and cardiovascular events?
Each year, as we develop the standards of care, we review all of the scientific and medical literature the year before. One of the things that really jumped out was the availability of new treatments to prevent progression of chronic kidney disease and congestive heart failure. Finerenone, a newly approved drug, has had some wonderful evidence and randomized controlled trials to do both of those things. And it was important that we update the standards so that clinicians could understand how they could use this new treatment modality.
